TRILLIUM THERAPEUTICS INC. : Other Events, Financial Statements and Exhibits (form 8-K)

Item 8.01. Other Events.

On October 28, 2021, Trillium Therapeutics Inc. ("Trillium") announced that it obtained a final order from the Supreme Court of British Columbia approving the previously announced plan of arrangement (the "Arrangement") under Division 5 of Part 9 of the Business Corporations Act (British Columbia) pursuant to the Arrangement Agreement, dated August 20, 2021 by and among Trillium, Pfizer Inc. ("Pfizer") and PF Argentum Acquisition ULC ("PF Argentum"), a wholly-owned indirect subsidiary of Pfizer.

The Arrangement is subject to regulatory approval and clearances, as well as other customary closing conditions. Subject to the satisfaction of such conditions, the transaction is expected to be completed in the fourth quarter of 2021 or the first half of 2022. Following closing of the Arrangement, Trillium's common shares will be delisted from the Toronto Stock Exchange and NASDAQ.

A copy of the press release issued by Trillium on October 28, 2021 is attached as Exhibit 99.1 to this Current Report on Form 8-K.

Item 9.01. Financial Statements and Exhibits.

(d) Exhibits:



Exhibit Number   Description
                   Press release issued by Trillium Therapeutics Inc. on
  99.1           October 28, 2021
                 Cover Page Interactive Data File (formatted as Inline XBRL and
104              embedded within the Inline XBRL document)

© Edgar Online, source Glimpses